Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureWenlong Wan, Fang Wei, Xiao Yu, Ziqi Wang, Jianping Miao, Ben Zhao
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Cancer statistics for African American and Black people, 2025
2025
CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway
10.1016/j.canlet.2021.03.012 · 2021
A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer
10.2147/ott.s186271 · 2019
Safety and activity of programmed cell death 1 versus programmed cell death ligand 1 inhibitors for platinum-resistant urothelial cancer: a meta-analysis of published clinical trials
2021
AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage
10.1038/s41401-022-01047-6 · 2023
Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma
10.1007/s10120-020-01066-4 · 2020
AXL and MET in hepatocellular carcinoma: a systematic literature review
10.1159/000520501 · 2022
AXL inhibition improves BRAF-targeted treatment in melanoma
10.1038/s41598-022-09078-z · 2022
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
Identifying key genes related to inflammasome in severe COVID-19 patients based on a joint model with random forest and artificial neural network
10.3389/fcimb.2023.1139998 · 2023
The Emerging Role of the IL-17B/IL-17RB Pathway in Cancer
10.3389/fimmu.2020.00718 · 2020
IL-17 inhibits CXCL9/10-mediated recruitment of CD8(+) cytotoxic T cells and regulatory T cells to colorectal tumors
10.1186/s40425-019-0757-z · 2019
10.4049/jimmunol.1800696
10.4049/jimmunol.1800696
IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells
10.1084/jem.20070406 · 2007
The central role of IL-17 in cancer stemness and immune evasion: a novel axis for overcoming immune checkpoint inhibitor resistance
2025
Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer
2022
The immune subtypes and landscape of squamous cell carcinoma
10.1158/1078-0432.ccr-18-4085 · 2019
Characterization of glycolysis-associated molecules in the tumor microenvironment revealed by pan-cancer tissues and lung cancer single cell data
10.3390/cancers12071788 · 2020
AXL: shapers of tumor progression and immunosuppressive microenvironments
10.1186/s12943-024-02210-9 · 2025
A combined risk score model to assess prognostic value in patients with soft tissue sarcomas
10.3390/cells11244077 · 2022
Axl inhibitor-mediated reprogramming of the myeloid compartment of the in vitro tumor microenvironment is influenced by prior targeted therapy treatment
10.3389/fimmu.2025.1601420 · 2025
Axl regulation of NK cell activity creates an immunosuppressive tumor immune microenvironment in head and neck cancer
10.3390/cancers17060994 · 2025
Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade
10.1158/0008-5472.can-20-0434 · 2021
Type 17 immunity promotes the exhaustion of CD8(+) T cells in cancer
10.1136/jitc-2021-002603 · 2021
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
10.1136/jitc-2020-001895 · 2021
Incorporation of SKI-G-801, a Novel AXL Inhibitor, with Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor activity and Survival by Enhancing T Cell Immunity
2022
SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models
10.1002/cti2.1364 · 2022
Axl and mertk receptors cooperate to promote breast cancer progression by combined oncogenic signaling and evasion of host antitumor immunity
10.1158/0008-5472.can-20-2066 · 2021
Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer
10.1038/s41419-024-06493-0 · 2024
Recent discovery and development of AXL inhibitors as antitumor agents
10.1016/j.ejmech.2024.116475 · 2024
Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer
10.1084/jem.20190354 · 2020
AXL kinase inhibition promotes cytosolic DNA sensor cGAS activity and sensitizes poorly immunogenic tumors to chemo-immunotherapy
2025
10.1073/pnas.2023868118
10.1073/pnas.2023868118
IL-17-induced HIF1α drives resistance to anti-PD-L1 via fibroblast-mediated immune exclusion
10.1084/jem.20210693 · 2022
IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer
10.1186/s12967-023-04365-3 · 2023
Spatial transcriptomics reveals that metabolic characteristics define the tumor immunosuppression microenvironment via iCAF transformation in oral squamous cell carcinoma
10.1038/s41368-023-00267-8 · 2024
Lingual denervation improves the efficacy of Anti-PD-1 immunotherapy in oral squamous cell carcinomas by downregulating TGFβ signaling
10.1158/2767-9764.crc-23-0192 · 2024
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial
10.1038/s41467-025-58179-6 · 2025
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
10.1016/j.lungcan.2023.107291 · 2023
S100A5 attenuates efficiency of anti-PD-L1/PD-1 immunotherapy by inhibiting CD8(+) T cell-mediated anti-cancer immunity in bladder carcinoma
2023
No additional external references are available.
